Annual report
9273.TEDINET S100P8UB
Period2021-07-01 → 2022-06-30
Filed2022-09-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥20.4bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥17.8bn | 2020-07-01 → 2021-06-30 | Cons. | Net sales |
| Revenue | ¥16.0bn | 2019-07-01 → 2020-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥15.2bn | 2018-07-01 → 2019-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.8bn | 2017-07-01 → 2018-06-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥3.4bn | 2020-07-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2020-07-01 → 2021-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.4bn | 2019-07-01 → 2020-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2018-07-01 → 2019-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2017-07-01 → 2018-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.4bn | 2020-07-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.1bn | 2020-07-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.7bn | 2019-07-01 → 2020-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥654m | 2018-07-01 → 2019-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥735m | 2017-07-01 → 2018-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2020-07-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥26.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥24.8bn | at 2021-06-30 | Cons. | Assets |
| Total assets | ¥22.9bn | at 2020-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥22.1bn | at 2019-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥21.6bn | at 2018-06-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.6bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥8.1bn | at 2021-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥18.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥16.7bn | at 2021-06-30 | Cons. | Net assets |
| Net assets / equity | ¥14.9bn | at 2020-06-30d | Cons. | Net assets |
| Net assets / equity | ¥13.4bn | at 2019-06-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥13.0bn | at 2018-06-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.3bn | at 2021-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2020-06-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2019-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.9bn | at 2018-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.1bn | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.1bn | 2020-07-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.3bn | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥385m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2017-07-01 → 2018-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥477m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥223m | 2020-07-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥547m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥244m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥867m | 2017-07-01 → 2018-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥805m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥679m | 2020-07-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥557m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥816m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥969m | 2017-07-01 → 2018-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥59.55 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.94 | 2020-07-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.05 | 2019-07-01 → 2020-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.5 | 2018-07-01 → 2019-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.59 | 2017-07-01 → 2018-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥471.14 | at 2022-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥421.61 | at 2021-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥376.48 | at 2020-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥338.45 | at 2019-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥327.77 | at 2018-06-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 71.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.3% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.1% | at 2020-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2019-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.1% | at 2018-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 13.3% | 2021-07-01 → 2022-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2020-07-01 → 2021-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.3% | 2019-07-01 → 2020-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2018-07-01 → 2019-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2017-07-01 → 2018-06-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 303 | at 2022-06-30 | Cons. | Number of employees |
| Employees | 303 | at 2021-06-30 | Cons. | Number of employees |
| Employees | 296 | at 2020-06-30d | Cons. | Number of employees |
| Employees | 310 | at 2019-06-30d | Cons. | Number of employees |
| Employees | 308 | at 2018-06-30d | Cons. | Number of employees |
| Revenue | ¥704m | 2021-07-01 → 2022-06-30 | Standalone | Operating revenue1 |
| Revenue | ¥638m | 2020-07-01 → 2021-06-30 | Standalone | Operating revenue1 |
| Revenue | ¥628m | 2019-07-01 → 2020-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥2.1bn | 2018-07-01 → 2019-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥557m | 2017-07-01 → 2018-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥86m | 2021-07-01 → 2022-06-30 | Standalone | Operating income |
| Operating income | ¥74m | 2020-07-01 → 2021-06-30 | Standalone | Operating income |
| Ordinary income | ¥89m | 2021-07-01 → 2022-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥78m | 2020-07-01 → 2021-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥142m | 2019-07-01 → 2020-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2018-07-01 → 2019-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥120m | 2017-07-01 → 2018-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥89m | 2021-07-01 → 2022-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥78m | 2020-07-01 → 2021-06-30 | Standalone | Income before income taxes |
| Net income | ¥95m | 2021-07-01 → 2022-06-30 | Standalone | Profit loss |
| Net income | ¥76m | 2020-07-01 → 2021-06-30 | Standalone | Profit loss |
| Net income | ¥160m | 2019-07-01 → 2020-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.5bn | 2018-07-01 → 2019-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥115m | 2017-07-01 → 2018-06-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥11.9bn | at 2022-06-30 | Standalone | Assets |
| Total assets | ¥12.1bn | at 2021-06-30 | Standalone | Assets |
| Total assets | ¥12.1bn | at 2020-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.9bn | at 2019-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.0bn | at 2018-06-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.7bn | at 2022-06-30 | Standalone | Liabilities |
| Total liabilities | ¥1.6bn | at 2021-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥10.3bn | at 2022-06-30 | Standalone | Net assets |
| Net assets / equity | ¥10.6bn | at 2021-06-30 | Standalone | Net assets |
| Net assets / equity | ¥10.8bn | at 2020-06-30d | Standalone | Net assets |
| Net assets / equity | ¥10.9bn | at 2019-06-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥9.6bn | at 2018-06-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥842m | at 2022-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2021-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥2.41 | 2021-07-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.93 | 2020-07-01 → 2021-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥4.04 | 2019-07-01 → 2020-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.94 | 2018-07-01 → 2019-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.06 | 2017-07-01 → 2018-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥11 | 2021-07-01 → 2022-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2020-07-01 → 2021-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥34 | 2019-07-01 → 2020-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2018-07-01 → 2019-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2017-07-01 → 2018-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥258.89 | at 2022-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥266.48 | at 2021-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥273.06 | at 2020-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥275.02 | at 2019-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥242.92 | at 2018-06-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 85.9% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2021-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2020-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.4% | at 2019-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.7% | at 2018-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 0.9% | 2021-07-01 → 2022-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.7% | 2020-07-01 → 2021-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2019-07-01 → 2020-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.6% | 2018-07-01 → 2019-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.2% | 2017-07-01 → 2018-06-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 39,619,980 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,619,980 | at 2021-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,904,995 | at 2020-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,904,995 | at 2019-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,301,665 | at 2018-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 22 | at 2022-06-30 | Standalone | Number of employees |
| Employees | 22 | at 2021-06-30 | Standalone | Number of employees |
| Employees | 20 | at 2020-06-30d | Standalone | Number of employees |
| Employees | 17 | at 2019-06-30d | Standalone | Number of employees |
| Employees | 18 | at 2018-06-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-07-01 → 2022-06-30 | ¥322,000 |
| Reconciling Itemsreconciling | depreciation | 2021-07-01 → 2022-06-30 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2022-06-30 | −¥1.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2022-06-30 | −¥1.9bn |
| Reconciling Itemsreconciling | segment assets | at 2022-06-30 | ¥108m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2022-06-30 | −¥4m |
| Drug Substance Sales Businessreportable segment | capex | 2021-07-01 → 2022-06-30 | ¥34m |
| Drug Substance Sales Businessreportable segment | depreciation | 2021-07-01 → 2022-06-30 | ¥92m |
| Drug Substance Sales Businessreportable segment | employees | at 2022-06-30 | 77 pure |
| Drug Substance Sales Businessreportable segment | revenue | 2021-07-01 → 2022-06-30 | ¥14.7bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2021-07-01 → 2022-06-30 | ¥12.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2021-07-01 → 2022-06-30 | ¥1.9bn |
| Drug Substance Sales Businessreportable segment | segment assets | at 2022-06-30 | ¥15.4bn |
| Drug Substance Sales Businessreportable segment | segment profit | 2021-07-01 → 2022-06-30 | ¥2.4bn |
| Pharmaceutical Marketing Businessreportable segment | capex | 2021-07-01 → 2022-06-30 | ¥353m |
| Pharmaceutical Marketing Businessreportable segment | depreciation | 2021-07-01 → 2022-06-30 | ¥582m |
| Pharmaceutical Marketing Businessreportable segment | employees | at 2022-06-30 | 204 pure |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2021-07-01 → 2022-06-30 | ¥7.5bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2021-07-01 → 2022-06-30 | ¥7.5bn |
| Pharmaceutical Marketing Businessreportable segment | segment assets | at 2022-06-30 | ¥10.7bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2021-07-01 → 2022-06-30 | ¥1.4bn |
| —segment total | capex | 2021-07-01 → 2022-06-30 | ¥387m |
| —segment total | depreciation | 2021-07-01 → 2022-06-30 | ¥674m |
| —segment total | employees | at 2022-06-30 | 281 pure |
| —segment total | revenue | 2021-07-01 → 2022-06-30 | ¥22.2bn |
| —segment total | revenue external | 2021-07-01 → 2022-06-30 | ¥20.4bn |
| —segment total | revenue intersegment | 2021-07-01 → 2022-06-30 | ¥1.9bn |
| —segment total | segment assets | at 2022-06-30 | ¥26.1bn |
| —segment total | segment profit | 2021-07-01 → 2022-06-30 | ¥3.8bn |
| Reconciling Itemsreconciling | capex | 2020-07-01 → 2021-06-30 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2020-07-01 → 2021-06-30 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2020-07-01 → 2021-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-07-01 → 2021-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | segment assets | at 2021-06-30 | ¥344m |
| Reconciling Itemsreconciling | segment profit | 2020-07-01 → 2021-06-30 | −¥65m |
| Drug Substance Sales Businessreportable segment | capex | 2020-07-01 → 2021-06-30 | ¥62m |
| Drug Substance Sales Businessreportable segment | depreciation | 2020-07-01 → 2021-06-30 | ¥85m |
| Drug Substance Sales Businessreportable segment | revenue | 2020-07-01 → 2021-06-30 | ¥12.5bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2020-07-01 → 2021-06-30 | ¥10.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2020-07-01 → 2021-06-30 | ¥1.7bn |
| Drug Substance Sales Businessreportable segment | segment assets | at 2021-06-30 | ¥14.3bn |
| Drug Substance Sales Businessreportable segment | segment profit | 2020-07-01 → 2021-06-30 | ¥2.2bn |
| Pharmaceutical Marketing Businessreportable segment | capex | 2020-07-01 → 2021-06-30 | ¥271m |
| Pharmaceutical Marketing Businessreportable segment | depreciation | 2020-07-01 → 2021-06-30 | ¥536m |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2020-07-01 → 2021-06-30 | ¥7.0bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2020-07-01 → 2021-06-30 | ¥7.0bn |
| Pharmaceutical Marketing Businessreportable segment | segment assets | at 2021-06-30 | ¥10.1bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2020-07-01 → 2021-06-30 | ¥1.2bn |
| —segment total | capex | 2020-07-01 → 2021-06-30 | ¥334m |
| —segment total | depreciation | 2020-07-01 → 2021-06-30 | ¥621m |
| —segment total | revenue | 2020-07-01 → 2021-06-30 | ¥19.5bn |
| —segment total | revenue external | 2020-07-01 → 2021-06-30 | ¥17.8bn |
| —segment total | revenue intersegment | 2020-07-01 → 2021-06-30 | ¥1.7bn |
| —segment total | segment assets | at 2021-06-30 | ¥24.5bn |
| —segment total | segment profit | 2020-07-01 → 2021-06-30 | ¥3.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,298
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2021-07-01 | |
| Current period end date | FilingDateInstant | 2022-06-30 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2022-06-30 | |
| Previous fiscal year start date | FilingDateInstant | 2020-07-01 | |
| Comparative period end date | FilingDateInstant | 2021-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2021-06-30 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Research and development activities (text) | FilingDateInstant | Text · Plus | |
| Overview of capital expenditures etc (text) | FilingDateInstant | Text · Plus | |
| Major facilities (text) | FilingDateInstant | Text · Plus | |
| Planned additions retirements etc of facilities (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Text · Plus | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Description of rights plan (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Shareholding by shareholder category (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)株式会社土師 | |
| Address major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)神奈川県横浜市港北区箕輪町2-17-5 | |
| Name major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)公益財団法人首藤奨学財団 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |